Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Oct 06, 2020 10:00 AM - Oct 07, 2020 5:25 PM

(US Eastern Standard Time)

Fort Washington, PA 19034

Biosimilars Conference

Session 4: A Success of Our Own: How Do We Define the U.S.’ Biosimilar Success Story?

Session Chair(s)

Leah  Christl, PhD

Leah Christl, PhD

Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy

Amgen, United States

Tiffany  Fletcher, MA

Tiffany Fletcher, MA

Head of Global Access Policy

Viatris, United States

The Biologics Price Competition and Innovation Act was signed into law on March 23, 2010 creating an abbreviated approval pathway for biosimilar medicines. The first biosimilar was approved in the US in 2015. As of today, FDA has approved 26 biosimilars and 17 have launched into the US market. As we analyze how the market has developed over the last 10 years, it is important to understand the progression of the market and answer an important question: What does success look like for the biosimilars in the U.S.? We will discuss the following:

  • What are the metrics of success?
  • Does the measure of success differ between product types, sites of care, disease states, & stakeholder groups?
  • What is the vision of success that is or is not being met today?
  • What is the U.S.’ definition of biosimilar market “equilibrium”? (i.e., the balance between success and failure)
  • In what ways are biosimilars addressing health disparities and access to care, and should this factor into the evaluation of success?
  • How are biosimilars laying the groundwork for the appropriate amount of reinvestment in innovation?

Learning Objective :
  • Evaluate the current development of the biosimilar market in the U.S.
  • Define the appropriate metrics to measure the success/failure of the US biosimilars market
  • Analyze the impact of biosimilar competition in the US on market access and healthcare economics
  • Compare/contrast the differing levels of success for the different products and sites of care
  • Create a framework for assessing the future success of biosimilars in the U.S.

Speaker(s)

Ronny  Gal, PhD

Speaker

Ronny Gal, PhD

AllianceBernstein LP, United States

Senior Research Analyst

Chad  Pettit, MBA

Speaker

Chad Pettit, MBA

Amgen Inc., United States

Executive Director, Marketing, Global Biosimilars Commercial Lead

Chrys  Kokino, MBA

Speaker

Chrys Kokino, MBA

Accord BioPharma, United States

Head of Global Biologics Commercial

Kevin Brian Knopf, MD, MPH

Speaker

Kevin Brian Knopf, MD, MPH

Highland Hospital, United States

Division Chief Hematology/Oncology

Mohannad  Kusti, MD, MPH

Speaker

Mohannad Kusti, MD, MPH

Pivot Onsite Innovations, United States

Regional Medical Director

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.